St. Jude Medical Inc. (NYSE:STJ) announced today that it won U.S. Food & Drug Administration clearance for its Epiducer lead delivery system for neurostimulation in treatment of chronic pain.
The clearance is the first of its kind for the U.S. The device allows physicians to place multiple neurostimulation leads and different types of leads through a single entry point, reducing the need for the multiple incisions typically required.